Please assess the completion status of the following clinical trial:

Trial Title: Chemotherapy Based on PET Scan in Treating Patients With Stage I or Stage II Hodgkin Lymphoma

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Histologically proven classical Hodgkin lymphoma subclassified according to the World Health Organization (WHO) Classification of Tumors, 4th edition (2008)~* Patients must have clinical stage IA, IB, IIA, or IIB disease~  * Patients with E extensions will be eligible if all other criteria have been met~* Patients must have a mediastinal mass \> 0.33-cm maximum intrathoracic diameter on standing postero-anterior chest x-ray or measuring \> 10 cm in its largest diameter on axial CT images~* Bone marrow biopsy is required~* ECOG performance status 0-2~* ANC ≥ 1,000/μL~* Platelet count ≥ 100,000/μL~* Hemoglobin ≥ 10 g/dL~* Serum creatinine ≤ 2 mg/dL~* Direct bilirubin ≤ 2 mg/dL~* AST/ALT ≤ 2 times upper limit of normal~* Women of childbearing potential and sexually active males must be strongly advised to use an accepted and effective method of contraception~* LVEF by ECHO or MUGA normal unless thought to be disease related~* DLCO ≥ 60% with no symptomatic pulmonary disease unless thought to be disease related~* Patients with a history of intravenous drug abuse, or any behavior associated with an increased risk of HIV infection, should be tested for exposure to the HIV virus, and an HIV test is required for entry on this protocol~* HIV-positive patients are eligible if they have CD4 counts ≥ 400/mm³ and are on concurrent antiretrovirals~  * Patient HIV status must be known prior to registration~ * HIV-positive patients must not have multi-drug resistant HIV infections; CD4 counts \< 400/mm³; or other concurrent AIDS-defining conditions~* Concurrent antiretroviral therapy for HIV-positive patients (CD4 counts ≥ 400/mm³) allowed~Exclusion Criteria:~* Nodular lymphocyte-predominant Hodgkin lymphoma~* Pregnant or nursing~* Currently active second malignancy other than non-melanoma skin cancers~  * Patients are not considered to have a currently active malignancy if they have completed therapy and are considered by their physician to be at less than 30% risk of relapse~* Prior treatment (chemotherapy or radiation therapy) for Hodgkin lymphoma

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- ABVD + INRT (Type: EXPERIMENTAL): Induction ABVD chemotherapy: Patients receive doxorubicin hydrochloride IV, bleomycin sulfate IV, vinblastine IV over 3-5 minutes, and dacarbazine IV over 30 minutes on days 1 and 15. Treatment repeats every 28 days for 2 courses.~PET-CT scan: Then patients undergo fludeoxyglucose F 18 (18 FDG) positron emission tomography (PET)/computed tomography (CT). If results are negative, patients receive the following treatment.~ABVD + INRT: Patients receive doxorubicin hydrochloride, bleomycin sulfate, vinblastine, and dacarbazine as in induction chemotherapy. Treatment repeats every 28 days for 4 courses. Within 3-6 weeks after completion of chemotherapy, patients undergo involved-node radiotherapy (INRT) 5 days a week for approximately 3½ weeks.
- ABVD + BEACOPP + INRT (Type: EXPERIMENTAL): Induction ABVD chemotherapy: Patients receive doxorubicin hydrochloride IV, bleomycin sulfate IV, vinblastine IV over 3-5 minutes, and dacarbazine IV over 30 minutes on days 1 and 15. Treatment repeats every 28 days for 2 courses.~PET-CT scan: Then patients undergo fludeoxyglucose F 18 (18 FDG) positron emission tomography (PET)/computed tomography (CT). If results are positive, patients receive the following treatment.~BEACOPP + INRT: Patients receive doxorubicin hydrochloride IV and cyclophosphamide IV over 60 minutes on day 1, etoposide IV over 60 minutes on days 1-3, procarbazine hydrochloride orally (PO) on days 1-7, prednisone PO on days 1-14, and bleomycin sulfate IV and vincristine sulfate IV on day 8. Treatment repeats every 21 days for 4 courses. Within 3-6 weeks after completion of chemotherapy, patients who achieve complete response with a negative 18FDG-PET/CT scan undergo INRT 5 days a week for approximately 3½ weeks.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues